Angiogenic balance (sFlt-1/PlGF) and preeclampsia

Annales d'Endocrinologie

Volumn 77, Issue 2, 2016, Pages 97-100

  Lecarpentier, Edouard ^a,b,c,d,e   Tsatsaris, Vassilis ^a,b,c,d,e  

^a National Institute of Health Medical Research)   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c université Paris Cité   (France)

^d DHU Risques et Grossesse   (France)

^e Fondation PremUP   (France)

Author keywords

Placenta; PlGF; Preelampsia; SFlt 1

Indexed keywords

ACETYLSALICYLIC ACID; PLACENTAL GROWTH FACTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; FLT1 PROTEIN, HUMAN; PGF PROTEIN, HUMAN;

ANGIOGENESIS; ARTICLE; DISEASE SEVERITY; DOPPLER FLOWMETRY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; FIRST TRIMESTER PREGNANCY; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; INFLAMMATION; LOW DRUG DOSE; MATERNAL BLOOD; PATHOPHYSIOLOGY; PLACENTA INSUFFICIENCY; PODOCYTE; PREDICTIVE VALUE; PREECLAMPSIA; PROTEIN PROTEIN INTERACTION; RECEIVER OPERATING CHARACTERISTIC; TROPHOBLASTIC DISEASE; ECONOMICS; FEMALE; GENETICS; PHYSIOLOGY; PRE-ECLAMPSIA; PREGNANCY;

FEMALE; HEALTH CARE COSTS; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; PLACENTA GROWTH FACTOR; PRE-ECLAMPSIA; PREGNANCY; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84964579503     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ando.2016.04.007     Document Type: Article

References (22)

1. Sibai B., Dekker G., Kupferminc M. Pre-eclampsia. Lancet 2005, 365:785-799.
2. Steegers E.A.P., von Dadelszen P., Duvekot J.J., Pijnenborg R. Pre-eclampsia. Lancet 2010, 376:631-644.
3. Ancel P.-Y., Goffinet F. EPIPAGE 2: a preterm birth cohort in France in 2011. BMC Pediatr 2014, 14:97. EPIPAGE 2 Writing Group.
4. Gilbert W.M. The cost of preterm birth: the low cost versus high value of tocolysis. BJOG Int J Obstet Gynaecol 2006, 113:4-9.
5. Redman C.W., Sargent I.L. Latest advances in understanding preeclampsia. Science 2005, 308:1592-1594.
6. Maynard S., Epstein F.H., Karumanchi S.A. Preeclampsia and angiogenic imbalance. Annu Rev Med 2008, 59:61-78.
7. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004, 25:581-611.
8. Kendall R.L., Thomas K.A. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A 1993, 90:10705-10709.
9. Tsatsaris V., Goffin F., Munaut C., Brichant J.-F., Pignon M.-R., Noel A., et al. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab 2003, 88:5555-5563.
10. Fan X., Rai A., Kambham N., Sung J.F., Singh N., Petitt M., et al. Endometrial VEGF induces placental sFLT1 and leads to pregnancy complications. J Clin Invest 2014, 124:4941-4952.
11. Maynard S.E., Min J.-Y., Merchan J., Lim K.-H., Li J., Mondal S., et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003, 111:649-658.
12. Levine R.J., Maynard S.E., Qian C., Lim K.-H., England L.J., Yu K.F., et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004, 350:672-683.
13. Rana S., Powe C.E., Salahuddin S., Verlohren S., Perschel F.H., Levine R.J., et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012, 125:911-919.
14. Akolekar R., Syngelaki A., Poon L., Wright D., Nicolaides K.H. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther 2013, 33:8-15.
15. Parra-Cordero M., Rodrigo R., Barja P., Bosco C., Rencoret G., Sepúlveda-Martinez A., et al. Prediction of early and late pre-eclampsia from maternal characteristics, uterine artery Doppler and markers of vasculogenesis during first trimester of pregnancy. Ultrasound Obstet Gynecol 2013, 41:538-544.
16. Scazzocchio E., Figueras F., Crispi F., Meler E., Masoller N., Mula R., et al. Performance of a first-trimester screening of preeclampsia in a routine care low-risk setting. Am J Obstet Gynecol 2013, 208. [203e.1-10].
17. Odibo A.O., Zhong Y., Goetzinger K.R., Odibo L., Bick J.L., Bower C.R., et al. First-trimester placental protein-13, PAPP-A, uterine artery Doppler and maternal characteristics in the prediction of pre-eclampsia. Placenta 2011, 32:598-602.
18. Caradeux J., Serra R., Nien J.K., Pérez-Sepulveda A., Schepeler M., Guerra F., et al. First trimester prediction of early onset preeclampsia using demographic, clinical, and sonographic data: a cohort study. Prenat Diagn 2013, 33:732-736.
19. Oliveira N., Magder L.S., Blitzer M.G., Baschat A.A. First-trimester prediction of pre-eclampsia: external validity of algorithms in a prospectively enrolledcohort. Ultrasound Obstet Gynecol 2014, 44:279-285.
20. Sibiude J., Guibourdenche J., Dionne M.D., Le Ray C., Anselem O., Serreau R., et al. Placental growth factor for the prediction of adverse outcomes in patients with suspected preeclampsia or intrauterine growth restriction. PLoS One 2012, 7:e50208.
21. Chappell L.C., Duckworth S., Seed P.T., Griffin M., Myers J., Mackillop L., et al. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. Circulation 2013, 128:2121-2131.
22. Zeisler H., Llurba E., Chantraine F., Vatish M., Staff A.C., Sennström M., et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N Engl J Med 2016, 374:13-22.